Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Friday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their target price on shares of Aethlon Medical from $23.00 to $10.00 and set a buy rating on the stock in a report on Monday, March 4th.

Aethlon Medical Price Performance

AEMD stock opened at $1.45 on Friday. The company has a market cap of $3.80 million, a P/E ratio of -0.29 and a beta of 1.88. Aethlon Medical has a 1 year low of $1.40 and a 1 year high of $7.20. The firm has a 50-day moving average of $1.69 and a 200 day moving average of $1.78.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). On average, equities research analysts expect that Aethlon Medical will post -4.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in shares of Aethlon Medical by 11.6% in the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock valued at $395,000 after acquiring an additional 28,097 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Aethlon Medical during the third quarter worth about $72,000. Vanguard Group Inc. increased its position in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after purchasing an additional 558,596 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Aethlon Medical during the third quarter worth about $32,000. Finally, HRT Financial LP acquired a new stake in Aethlon Medical during the fourth quarter worth about $28,000. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.